Last reviewed · How we verify
NCT05570344
rTMS With and Without Text4Support for the Treatment of Resistant Depression.
NA trial testing Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressive Disorder, Treatment-Resistant in 200 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 February 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support
Conditions studied
- Depressive Disorder, Treatment-Resistant — all drugs for Depressive Disorder, Treatment-Resistant →
Sponsor
University of Alberta
Who can join
18 and older, any sex, with Depressive Disorder, Treatment-Resistant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter prospective, parallel design, two-arm, rater-blinded randomized controlled pilot trial. Participants will be randomly assigned to one of two treatment conditions. In the first condition, treatment consists of rTMS sessions combined with Text4Support. The second condition is made up of the treatment as usual (rTMS sessions alone). The recruitment process is scheduled to last 12 months. It will involve active treatment for six weeks and follow-up period observation periods of 1,3, and 6 months for participants in both arms of the study. Participants will be recruited from four different centers for this project. Two centers (the Addiction and Mental Health clinic and the Alberta day hospital) will be from the large, sociodemographic diverse city of Edmonton in Alberta Western Canada. The remaining two centers will be in Halifax and Annapolis Valley in Nova Scotia, Canada.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Repetitive Transcranial Magnetic Stimulation With and Without Text4Support for the Treatment of Resistant Depression: Protocol for a Patient-Centered Multicenter Randomized Controlled Pilot Trial.
Adu MK, Dias RDL, Agyapong B, Eboreime E, et al · · 2023 · PMID 38060308 · DOI 10.2196/46830
Verify or expand the search:
- PubMed search for NCT05570344
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Repetitive Transcranial Magnetic Stimulation (rTMS)
Trials testing the same drug.
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT06953596 — Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder · NA · not yet recruiting
- NCT06991062 — Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHAS · NA · recruiting
- NCT05426967 — rTMS for Military TBI-related Depression · NA · recruiting
- NCT06639594 — Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study · Phase 1 · recruiting
Other recruiting trials for Depressive Disorder, Treatment-Resistant
Currently open trials in the same condition.
- NCT07053345 — A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression · Phase 4 · recruiting
- NCT06668571 — Intravenous Ketamine for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06511908 — Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resi · Phase 2 · recruiting
- NCT05641623 — OSU6162 as add-on in SSRI/SNRI-resistant Depression · Phase 2 · recruiting
- NCT04469959 — Dopaminergic Dysfunction in Late-Life Depression · Phase 2 · active not recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05570344 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05570344.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing